CordLife Opens Banking Facility in Hong Kong
CyGenics, Ltd. announced that its subsidiary, CordLife, has opened a new cord blood processing and storage facility in Hong Kong. The facility brings the highest standards of cord blood processing and storage procedures to the market. The new facility is the cornerstone of CordLife's efforts in North Asia, in joint collaboration with leading venture capital firm, BS Fund Management. CyGenics owns 51% of the new entity, CordLife Hong Kong Pte Ltd, and BS Fund Management, 49%.
The companies have initially invested US$1 million to develop this market. CordLife's lead facility in Singapore has been in operations for three years, and has been very successful in providing cord blood banking services in that market and in Southeast Asia, in support of current autologous stem cell therapy and transplantation needs. The new Hong Kong facility, in addition to the full range of cord blood processing and storage capabilities, is backed by a full sales and marketing team, and is expected to be the lead facility for North Asia.
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Tepnel starts Construction of new state-of-the-art Scottish Laboratories
AEterna Zentaris Announces Completion of Patient Enrollment for Ozarelix Phase II Trial in Benign Prostatic Hyperplasia
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility - Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
